How IVIG Suppresses Immune Function
IVIG suppresses immune function through multiple complementary mechanisms: blocking Fc receptors on immune cells, inhibiting complement activation, diluting pathogenic antibodies, downregulating B-cell receptors, and modulating macrophage and dendritic cell function. 1, 2
Composition and Structure
IVIG is a concentrate of pooled immunoglobulins from 1,000-10,000 healthy donors, composed of approximately 90% IgG with small amounts of IgA, cytokines, and soluble receptors 1. The IgG molecule has a Y-shaped structure with:
- Fc portion (trunk): Binds to Fc-gamma receptors on immune cells and complement
- Fab fragment (arms): Binds antigens
Primary Mechanisms of Immune Suppression
1. Fc Receptor Blockade and Modulation
IVIG blocks antibody receptors on red blood cells and phagocytic cell surfaces, preventing uptake of autoantibody-coated cells 1. The Fc portion binds to Fc receptors present on nearly all immune cells, which can be either inhibitory or activatory 1.
- Stimulates inhibitory Fc-gamma receptors on macrophages, downregulating their phagocytic function 1, 2
- Reduces expression of activating FcγRIIa on myeloid dendritic cells (not upregulation of inhibitory FcγRIIb as previously thought) 3
- Modulates Fc-receptor mediated activity, leading to downregulation of phagocytosis 4
2. Antibody Dilution and Competitive Inhibition
IVIG dilutes maternal circulating pathogenic antibodies and competitively blocks placental Fc receptors, reducing transplacental transfer of pathogenic IgG 1. This mechanism is particularly relevant in hemolytic disease and transplant rejection.
3. Complement System Inhibition
IVIG inhibits complement activation, preventing the complement-mediated tissue damage that drives many autoimmune processes 2, 4, 2, 4.
4. Neutralization of Autoantibodies and Cytokines
IVIG contains anti-idiotypic antibodies that inhibit HLA-specific alloantibodies and neutralize circulating autoantibodies and cytokines 2. Polyclonal preparations have activity against:
- Class I and II HLA molecules
- Costimulatory molecules
- Cytokines and cytokine receptors
- T-cell receptors 2
5. B-Cell Receptor Downregulation
IVIG downregulates the B-cell receptor, reducing B-cell activation and antibody production 2.
6. Dendritic Cell and Macrophage Suppression
IVIG induces a cascade involving IL-33 production, which stimulates IL-4 and IL-13 secretion 3. These Th2 cytokines:
- Downregulate IFN-γ receptor 2 (IFN-γR2) on dendritic cells, suppressing their inflammatory responsiveness 3, 5
- Reduce FcγRIIa expression on myeloid dendritic cells 3
- Block IFN-γ signaling and gene expression, preventing macrophage activation 5
This mechanism operates through FcγRIII (an activating receptor) rather than the inhibitory FcγRIIb, revealing an unexpected inhibitory role for this receptor 5.
7. Direct T-Cell Suppression
IVIG acts directly on conventional T cells to suppress T-cell receptor (TCR) signaling 6. This occurs independently of regulatory T cells and involves:
- Impaired IκB degradation
- Blocked nuclear translocation of NFAT (nuclear factor of activated T cells)
- Suppressed MAPK (Erk1/2) activation 6
8. Influence on Antigen Recognition
IVIG influences antigen recognition by sensitized T cells, modulating their activation and response 4.
Clinical Implications
The immunosuppressive effects are dose-dependent, with high-dose IVIG (1-2 g/kg) required for immunomodulation in autoimmune conditions 4, while lower doses (400-600 mg/kg) suffice for antibody replacement in immunodeficiency 7.
Important caveat: The anti-inflammatory activity of IVIG is attributed to a minor species of IgGs modified with terminal sialic acids on their Fc-linked glycans 8. Highly sialylated IgG glycovariants are essential for therapeutic activity 9.
The mechanisms work synergistically rather than in isolation, creating a multi-pronged suppression of both innate and adaptive immune responses that accounts for IVIG's broad efficacy across diverse autoimmune and inflammatory conditions.